Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer
- 545 Downloads
Mutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor.
In this retrospective study, KRAS and BRAF mutations were analyzed using a direct sequence method in 254 Japanese CRC patients, and the associations between KRAS or BRAF mutations and clinicopathological characteristics or outcome were evaluated.
KRAS and BRAF mutations were detected in 33.5 and 6.7 % of all patients, respectively. Consistent with previous reports, BRAF mutations were significantly correlated with the anatomical site of the tumor (P < 0.001), tumor grade (P = 0.001) and high frequency of microsatellite instability (P < 0.001). BRAF mutations were correlated with poor overall survival in the full patient cohort (P = 0.009). KRAS mutations were significantly correlated with poor recurrence-free survival (P = 0.03), particularly in patients with stage II CRC (P = 0.007). Cox regression analysis showed that KRAS mutations were a negative predictor of recurrence-free survival in patients with stage II CRC.
KRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II CRC.
KeywordsKRAS and BRAF mutations Colorectal cancer Prognostic factor
We thank Ms. Noriko Makikusa and Ms. Naoko Katakura for their technical assistance.
Conflict of interest
We declare that we have no conflict of interest.
- 5.Sylvester BE, Huo D, Khramtsov A et al (2012) Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 18:350–359Google Scholar
- 7.Moosmann N, von Weikersthal LF, Vehling-Kaiser U et al (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol 29:1050–1058PubMedCrossRefGoogle Scholar
- 14.Jass JR, Sobin LH (1989) Histological typing of intestinal tumours. WHO international histological classification of tumours no. 15, 2nd edn. Springer, BerlinGoogle Scholar
- 15.Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New YorkGoogle Scholar
- 24.Greenberg PL, Attar E, Bennett JM et al (2011) NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw 9:30–56Google Scholar
- 31.Bertagnolli MM, Redston M, Compton CC et al (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer—a study of CALGB 9581 and 89803. J Clin Oncol 29:3153–3162PubMedCentralPubMedCrossRefGoogle Scholar